| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49bb33af20cdfeb5d842e00801e3b58e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed3a4131f0a6568ef56fa0aae7154971
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_940cae6950206aba124a08aaa43b8c50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c591d455d21860f40660cc54639294ce |
| publicationDate |
2020-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3743061-A1 |
| titleOfInvention |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| abstract |
This invention provides processes and compositions for enhancing the immunogenicity of tumor or infected cells by increasing expression of major histocompatibility complex (MHC) class I surface molecules. Tumor cells often circumvent immune recognition by reducing or eliminating MHC expression. The lack of MHC on their surface allows tumor cells to evade immune detection and enables uncontrolled growth. Similarly, certain viral or microbial infections result in MHC class I downregulation and the resulting immune evasion. With a unique reporter assay, we have determined that some cannabinoid compounds and structural analogs can increase MHC class I expression on tumor cells grown in cell culture. The increase of tumor and infected cell MHC class I expression will enable detection and destruction by cytotoxic T-lymphocyte cells. The process and compositions increase the immunogenicity of the target cells, e.g. tumor or infected cells, to enhance their destruction by cytotoxic lymphocytes. When administered in combination, such compositions may enhance the activity of immune- oncology and anti-infectious disease agents. |
| priorityDate |
2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |